Glioma Grading: Sensitivity, Specificity, and Predictive Values of Perfusion MR Imaging and Proton MR Spectroscopic Imaging Compared with Conventional MR Imaging

American Journal of Neuroradiology

Volumn 24, Issue 10, 2003, Pages 1989-1998

  Law, Meng ^a   Yang, Stanley ^a   Wang, Hao ^b   Babb, James S ^a,b   Johnson, Glyn ^a   Cha, Soonmee ^c   Knopp, Edmond A ^a   Zagzag, David ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; N ACETYLASPARTIC ACID;

ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD VOLUME; BRAIN CIRCULATION; BRAIN PERFUSION; BRAIN REGION; CALCULATION; CHILD; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DEVICE; DISEASE SEVERITY; ERROR; FEMALE; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; METABOLITE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PROTON NUCLEAR MAGNETIC RESONANCE; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASPARTIC ACID; BLOOD VOLUME; BRAIN NEOPLASMS; CEREBROVASCULAR CIRCULATION; CHILD; CHILD, PRESCHOOL; CHOLINE; CREATINE; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 0345254996     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Kelly PJ, Daumas-Duport C, Scheithauer BW, et al. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987;62:450-459
2. Brant-Zawadzki M, Berry I, Osaki L, et al. Gd-DTPA in clinical MR of the brain: I. Intraaxial lesions. AJR Am J Roentgenol 1986;147:1223-1230
3. Brant-Zawadzki M, Badami JP, Mills CM, et al. Primary intracranial tumor imaging: a comparison of magnetic resonance and CT. Radiology 1984;150:435-440
4. Bydder GM, Steiner RE, Young IR, et al. Clinical NMR imaging of the brain: 140 cases. AJR Am J Roentgenol 1982; 139:215-236
5. Just M, Thelen M. Tissue characterization with TI, T2, and proton density values: results in 160 patients with brain tumors. Radiology 1988;169:779-785
6. Felix R, Schorner W, Laniado M, et al. Brain tumors: MR imaging with gadolinium-DTPA. Radiology 1985;156:681-688
7. Moller-Hartmann W, Herminghaus S, Krings T, et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002;44:371-381
8. Dean BL, Drayer BP, Bird CR, et al. Gliomas: classification with MR imaging. Radiology 1990;174:411-415
9. Watanabe M, Tanaka R, Takeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology 1992;34:463-469
10. Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J Neurosurg 1993;79:533-536
11. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999;211:791-798
12. Ginsberg LE, Fuller GN, Hashmi M, et al. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 1998; 49:436-440
13. Daumas-Duport C, Scheithauer B, O'Fallon J, et al. Grading of astrocytomas: a simple and reproducible method. Cancer 1988;62: 2152-2165
14. Burger PC, Vogel FS, Green SB, et al. Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications. Cancer 1985;56:1106-1111
15. Burger P. Malignant astrocytic neoplasms: classification, pathology, anatomy, and response to therapy. Semin Oncol 1986;13:16-20
16. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41-51
17. Bruening R, Kwong KK, Vevea MJ, et al. Echo-planar MR determination of relative cerebral blood volume in human brain tumors: T1 versus T2 weighting. AJNR Am J Neuroradiol 1996;17:831-840
18. Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998;171:1479-1486
19. Sugahara T, Korogi Y, Shigematsu Y, et al. Value of dynamic susceptibility contrast magnetic resonance imaging in the evaluation of intracranial tumors. Top Magn Reson Imaging 1999;10:114-124
20. Wong ET, Jackson EF, Hess KR, et al. Correlation between dynamic MRI and outcome in patients with malignant gliomas. Neurology 1998;50:777-781
21. Wong JC, Provenzale JM, Petrella JR. Perfusion MR imaging of brain neoplasms. Am J Roentgenol 2000;174:1147-1157
22. Cha S, Knopp EA, Johnson G, et al. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002;223:11-29
23. Lev MH, Rosen BR. Clinical applications of intracranial perfusion MR imaging. Neuroimaging Clin N Am 1999;9:309-331
24. Shin JH, Lee HK, Kwun BD, et al. Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas: preliminary results. Am J Roentgenol 2002;179:783-789
25. Petrella JR, Provenzale JM. MR perfusion imaging of the brain: techniques and applications. Am J Roentgenol 2000;175:207-219
26. Adamson AJ, Rand SD, Prost RW, et al. Focal brain lesions: effect of single-voxel proton MR spectroscopic findings on treatment decisions. Radiology 1998;209:73-78
27. Alger JR, Frank JA, Bizzi A, et al. Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F- 18 fluorodeoxyglucose PET. Radiology 1990;177:633-641
28. Arnold DL, Shoubridge EA, Villemure JG, et al. Proton and phosphorus magnetic resonance spectroscopy of human astrocytomas in vivo: preliminary observations on tumor grading. NMR Biomed 1990;3:184-189
29. Bruhn H, Frahm J, Gyngell ML, et al. Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors. Radiology 1989;172: 541-548
30. Castillo M, Kwock L. Clinical applications of proton magnetic resonance spectroscopy in the evaluation of common intracranial tumors. Top Magn Reson Imaging 1999;10:104-113
31. Castillo M, Smith JK, Kwock L. Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am J Neuroradiol 2000;21:1645-1649
32. Chang L, McBride D, Miller BL, et al. Localized in vivo IH magnetic resonance spectroscopy and in vitro analyses of heterogeneous brain tumors. J Neuroimaging 1995;5:157-163
33. Cheng LL, Chang IW, Louis DN, et al. Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. Cancer Res 1998;58:1825-1832
34. Danielson ER, Ross BD. Magnetic Resonance Spectroscopy of Neurological Diseases. New York, NY: Marcel Dekker Inc., 1998
35. Dowling C, Bollen AW, Noworolski SM, et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol 2001;22:604-612
36. Falini A, Calabrese G, Origgi D, et al. Proton magnetic resonance spectroscopy and intracranial tumours: clinical perspectives. J Neurol 1996;243:706-714
37. Fountas KN, Kapsalaki EZ, Gotsis SD, et al. In vivo proton magnetic resonance spectroscopy of brain tumors. Stereotact Funct Neurosurg 2000;74:83-94
38. Fulham MJ, Bizzi A, Dietz MJ, et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 1992;185:675-686
39. Kaminogo M, Ishimaru H, Morikawa M, et al. Diagnostic potential of short echo time MR spectroscopy of gliomas with single-voxel and point-resolved spatially localised proton spectroscopy of brain. Neuroradiology 2001;43:353-363
40. Kugel H, Heindel W, Ernestus RI, et al. Human brain tumors: spectral patterns detected with localized H-1 MR spectroscopy. Radiology 1992;183:701-709
41. Butzen J, Prost R, Chetty V, et al. Discrimination between neoplastic and nonneoplastic brain lesions by use of proton MR spectroscopy: the limits of accuracy with a logistic regression model. AJNR Am J Neuroradiol 2000;21:1213-1219
42. Luyten PR, Marien AJ, Heindel W, et al. Metabolic imaging of patients with intracranial tumors: H-1 MR spectroscopic imaging and PET. Radiology 1990;176: 791-799
43. McBride DQ, Miller BL, Nikas DL, et al. Analysis of brain tumors using 1H magnetic resonance spectroscopy. Surg Neurol 1995;44: 137-144
44. McKnight TR, Noworolski SM, Vigneron DB, et al. An automated technique for the quantitative assessment of 3D-MRSI data from patients with glioma. J Magn Reson Imaging 2001;13:167-177
45. Meyerand ME, Pipas JM, Mamourian A, et al. Classification of biopsy-confirmed brain tumors using single-voxel MR spectroscopy. AJNR Am J Neuroradiol 1999;20:117-123
46. Negendank WG, Sauter R, Brown TR, et al. Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg 1996;84:449-458
47. Nelson SJ. Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors. Magn Reson Med 2001;46:228-239
48. Ott D, Hennig J, Ernst T. Human brain tumors: assessment with in vivo proton MR spectroscopy. Radiology 1993;186:745-752
49. Poptani H, Gupta RK, Roy R, et al. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. AJNR Am J Neuroradiol 1995;16:1593-1603
50. Preul MC, Caramanos Z, Collins DL, et al. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med 1996;2:323-325
51. Rand SD, Prost R, Haughton V, et al. Accuracy of single-voxel proton MR spectroscopy in distinguishing neoplastic from nonneoplastic brain lesions. AJNR Am J Neuroradiol 1997;18:1695-1704
52. Ross B, Michaelis T. Clinical applications of magnetic resonance spectroscopy. Magn Reson Q 1994;10:191-247
53. Rutter A, Hugenholtz H, Saunders JK, et al. Classification of brain tumors by ex vivo 1H NMR spectroscopy. J Neurochem 1995;64: 1655-1661
54. Shimizu H, Kumabe T, Tominaga T, et al. Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. AJNR Am J Neuroradiol 1996;17:737-747
55. Tedeschi G, Lundbom N, Raman R, et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 1997;87:516-524
56. Wilken B, Dechent P, Herms J, et al. Quantitative proton magnetic resonance spectroscopy of focal brain lesions. Pediatr Neurol 2000; 23:22-31
57. Tamiya T, Kinoshita K, Ono Y, et al. Proton magnetic resonance spectroscopy reflects cellular proliferative activity in astrocytomas. Neuroradiology 2000;42:333-338
58. Shimizu H, Kumabe T, Shirane R, et al. Correlation between choline level measured by proton MR spectroscopy and Ki-67 labeling index in gliomas. AJNR Am J Neuroradiol 2000;21:659-665
59. Yang D, Korogi Y, Sugahara T, et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical- shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI. Neuroradiology 2002;44:656-666
60. Law M, Cha S, Knopp EA, et al. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002;222:715-721
61. Henry RG, Vigneron DB, Fischbein NJ, et al. Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas. AJNR Am J Neuroradiol 2000;21:357-366
62. Tzika AA, Vajapeyam S, Barnes PD. Multivoxel proton MR spectroscopy and hemodynamic MR imaging of childhood brain tumors: preliminary observations. AJNR Am J Neuroradiol 1997;18: 203-218
63. Lev MH. Gliomatosis cerebri has normal relative blood volume: really?! Who cares? Should you? AJNR Am J Neuroradiol 2002;23: 345-346
64. Ringertz J. Grading of gliomas. Acta Pathol Microbiol Scand 1950; 27:51-64
65. Wetzel SG, Cha S, Johnson G, et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002;224:797-803
66. Lin AP, Ross BD. Short-echo time proton MR spectroscopy in the presence of gadolinium. J Comput Assist Tomogr 2001;25:705-712
67. Murphy PS, Dzik-Jurasz AS, Leach MO, et al. The effect of Gd-DTPA on T1-weighted choline signal in human brain tumours. Magn Reson Imaging 2002;20:127-130
68. Smith JK, Kwock L, Castillo M. Effects of contrast material on single-volume proton MR spectroscopy. AJNR Am J Neuroradiol 2000;21:1084-1089
69. Tate AR, Majos C, Moreno A, et al. Automated classification of short echo time in in vivo 1H brain tumor spectra: a multicenter study. Magn Reson Med 2003;49:29-36
70. Nelson JS, Tsukada Y, Schoenfeld D, et al. Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer 1983;52:550-554
71. Li X, Lu Y, Pirzkall A, et al. Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients. J Magn Reson Imaging 2002;16:229-237
72. Carpinelli G, Carapella CM, Palombi L, et al. Differentiation of glioblastoma multiforme from astrocytomas by in vitro 1H MRS analysis of human brain tumors. Anticancer Res 1996;16:1559-1563
73. McKnight TR, von dem Bussche MH, Vigneron DB, et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002;97:794-802
74. Isobe T, Matsumura A, Anno I, et al. Quantification of cerebral metabolites in glioma patients with proton MR spectroscopy using T2 relaxation time correction. Magn Reson Imaging 2002;20:343-349
75. Cha S, Knopp EA, Johnson G, et al. Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol 2000; 21:881-890
76. Nelson SJ, Huhn S, Vigneron DB, et al. Volume MRI and MRSI techniques for the quantitation of treatment response in brain tumors: presentation of a detailed case study. J Magn Reson Imaging 1997;7:1146-1152
77. Nelson SJ, Vigneron DB, Dillon WP. Serial evaluation of patients with brain tumors using volume MRI and 3D 1H MRSI. NMR Biomed 1999;12:123-138